Opioid Use Disorder Market Size, Share, Competitive Landscape and Trend Analysis Report, by Drug Type, by Age group, by Route of Administration, by Distribution channal : Global Opportunity Analysis and Industry Forecast, 2021-2031

Opioid Use Disorder Market Research, 2031

The global opioid use disorder market was valued at $2.8 billion in 2021, and is projected to reach $8.1 billion by 2031, growing at a CAGR of 11.5% from 2022 to 2031. Opioids are a group of painkillers that include drugs that relax muscles, reduce pain, and relieve stress. Medications including hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids are prescribed to relieve moderate- to severe pain. The chronic, relapsing brain illness known as opioid usage disorder (OUD) is characterized by excessive opioid seeking and use despite side effects. It is regarded as a brain condition because it involves functional changes to brain circuits related to motivation, stress, self-control, and decision-making, and because those changes may endure for a considerable amount of time after drug use has stopped. An overwhelming want to use opioids, increased opioid tolerance, and withdrawal symptoms after cessation are all symptoms of opioid use disorder.

Growth of the global opioid use disorder market size is majorly driven by rise in the prevalence of chronic diseases such as cancer, cardiovascular diseases and orthopedic diseases anticipated to drive the opioid use disorder market growth. Increase in the number of chronic diseases cause rise in the incidence of surgical intervention. Opioid drugs are used to treat pain after surgery. This factor can cause addiction of opioid drugs even after decrease in pain. Thus, rise in the prevalence of chronic diseases anticipated fuel the demand of opioids use disorder drugs which boosts the market growth. For instance, as per the report of the National Cancer Institute, in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S.

Moreover, rise in product launch and product approval for opioid use disorder drugs anticipated to fuel the growth of opioid use disorder market. For instance, in May 2020, Indivior PLC, a pharmaceutical company in U.S., announced the approval of Subutex from Swedish Medical Products Agency (MPA). Subutex prolonged release solution for injection, 100 and 300mg for substitution treatment of opioid dependence in adults and adolescents over 16 years of age. Moreover, in February 2019, Indivior PLC, a pharmaceutical company, announced the launch of generic version of SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) in the U.S. used to treat opioid use disorders.

In addition, rising consideration of buprenorphine patches as an effective treatment mode fuels the market growth. Buprenorphine patches are becoming increasingly popular as an effective treatment for opioid use disorder, which is anticipated to the growth of opioid use disorder market. Patches containing buprenorphine are regarded as a cutting-edge method for treating opioid use disorder. Transdermal patches offer a number of benefits over other forms of treatment, such as injections, including the most pleasant drug delivery system, excellent pain relief, and self-administration of drug. In addition, rise in adoption of key strategies such as collaboration, acquisition, agreement and partnership by opioid industry of opioids use disorder fuels the growth of market. For instance, in February 2019, Indivior PLC, a pharmaceutical company, announced agreement with Alvogen Pine Brook LLC, a pharmaceutical company for sell of generic buprenorphine and naloxone sublingual film product unless and until the U.S. On the other hand, side effects associated opioids use disorder drugs anticipated to hinder the growth of opioid use disorder market growth.

Opioid Use Disorder Market Segmentation

The opioid use disorder market size is segmented into drug type, age group, route of administration and distribution channal, and region. On the basis of type, the market is segmented into agonist and antagonist. The agonist segment further sub-categorized into methadone and buprenorphine. Depending on age group, the market is classified into 19-39, 40-59 and age 60 and over. By route of administration, the market is classified into oral, intravenous and sublingual. On the basis of distribution channel, the market is divided into hospital pharmacy, retail pharmacy. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

The agonist segment dominated the opioid use disorder market share in 2021, and is expected to continue this trend throughout the forecast period, owing to Rise in the prevalence of chronic pain, high prevalence of opioid abuse and rising geriatric population prone to painful disease. However, antagonist segment is expected to witness considerable growth during the opioid use disorder market forecast period, owing to increase in research & development expenditure by major players, strategic alliances among key companies, and ongoing research on naltrexone drugs.

The 19 to 39 segment dominated the market in 2021, and is expected to continue this trend throughout the forecast period, owing to rise in the prevalence of chronic diseases such as cancer, cardiovascular diseases and orthopedic diseases associated with chronic pain.

The intravenous segment dominated the market in 2021, and is expected to continue this trend throughout the forecast period, owing to rise in the demand of intravenous route for the treatment of opioids use disorder treatment.

The hospital pharmacy segment dominated the market in 2021, and is expected to continue this trend throughout the forecast period, owing to rise in number of hospital pharmacy, increase in expenditure by government to develop healthcare infrastructure and increase in the prevalence of opioids use disorder.

The North America market was dominant, in terms of revenue among other regions in 2021, owing to increase the number of product launch and product approval for opioids use disorder, increase in the prevalence of chronic diseases such as cancer, cardiac diseases and orthopedic diseases and well-established opioid industry in North America. On the other hand, Asia-Pacific was the second-largest contributor in the market in 2021, and is expected to register fastest CAGR during the forecast period, owing to the number of geriatric populations, rise in the awareness regarding availability of healthcare services and increase in the number of chronic diseases.      

Some of the major companies that operate in the global opioid use disorder market include Alkermes, AstraZeneca Plc., BioDelivery Sciences International Inc., Braeburn, Camurus, Cerebral, Dr Reddy, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, NYC Health + Hospitals, Orexo AB, Pear Therapeutics, Pfizer, Reckitt Benckiser Pharmaceuticals Inc., Sandoz (Novartis), Titan Pharmaceuticals, Inc., Viatris Inc.                          

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioid use disorder market analysis from 2021 to 2031 to identify the prevailing opioid use disorder market opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the opioid use disorder market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global opioid use disorder market trends, key players, market segments, application areas, and market growth strategies.

  Opioid Use Disorder Market Report Highlights

Aspects	Details
By Drug Type	Agonist Type Methadone Buprenorphine Antagonist
By Age group	19 to 39 40 to 59 Age 60 and over
By Route of Administration	Oral Intravenous Sublingual
By Distribution channal	Hospital pharmacy Retail Pharmacy
By Region	North America  (U.S., Canada, Mexico) Europe  (Germany, France, UK, Italy, Spain, Rest of Europe) Asia-Pacific  (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific) LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players	Orexo AB, Titan Pharmaceuticals, Inc., Viatris Inc, Camurus, NYC Health Hospitals, OREXO AB, BioDelivery Sciences International Inc.,, Alkermes, Inc., Reckitt Benckiser Pharmaceuticals Inc, Pear Therapeutics, Dr Reddy Laboratories Ltd, Sandoz, AstraZeneca plc, mallinckrodt pharmaceuticals, braeburn pharmaceuticals, Hikma Pharmaceuticals PLC,, Indivior PLC

Analyst Review

Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. The opioid use disorder market is expected to witness growth during the forecast period owing to, rise in the prevalence of chronic diseases such as cardiovascular disease, cancer and others, increase in the product launch and product approval for opioids use disorder drugs and increasing cases of opioid addiction.

Rise in adoption of key strategies such as collaboration, acquisition, agreement and partnership by key players of opioids use disorder fuels the growth of market. For instance, in February 2019, Indivior PLC, a pharmaceutical company, announced agreement with Alvogen Pine Brook LLC, a pharmaceutical company for sell of generic buprenorphine and naloxone sublingual film product unless and until the U.S. Moreover, in February 2021, Orexo AB announced its collaboration with ApexB.io biotechnology research company to further research on the use of Modia. This product is a digital therapeutic designed for patients with opioid use disorder

Author Name(s) : Linu Dash | Roshan Deshmukh

Related Tags

• Drug Abuse
• Antidepressant Drugs
• Neurology

^*Terms and Conditions Apply